Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer.
Saved in:
| Title: | Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer. |
|---|---|
| Authors: | Kumaraswamy A; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Hu YM; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Yates JA; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Zhang C; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Rodansky E; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Khokhani D; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Flores D; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Duan Z; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Zhang Y; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Tabatabaei S; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Slottke R; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Ye S; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Lara P; University of California Davis, Davis, CA, USA., Foye A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Ryan CJ; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.; Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA., Quigley DA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA.; Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA., Huang J; Duke University, Durham, NC, USA., Aggarwal R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Reiter RE; Departments of Medicine and Urology, University of California Los Angeles, Los Angeles, CA, USA., Wicha MS; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Beer TM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Rettig M; Departments of Medicine and Urology, University of California Los Angeles, Los Angeles, CA, USA.; Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA., Gleave M; Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.; Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada., Evans CP; University of California Davis, Davis, CA, USA., Witte ON; Department of Microbiology, Immunology, and Molecular Genetics at the David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Stuart JM; Genomics Institute and Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA, USA., Thomas GV; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Feng FY; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Departments of Radiation Oncology and Urology, University of California San Francisco, San Francisco, CA, USA., Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Xia Z; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA. xiaz@ohsu.edu.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. xiaz@ohsu.edu., Alumkal JJ; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. jalumkal@med.umich.edu.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. jalumkal@med.umich.edu. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2025 Jul 07; Vol. 9 (1), pp. 223. Date of Electronic Publication: 2025 Jul 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-025-01002-8 |
